Resolomics is a biotechnology company developing innovative, high-value companion diagnostics and a novel cell-based therapy.
Our proprietary technology can identify specific molecules, lipid mediators, that are directly associated with both the initiation and resolution of inflammation, thereby enabling segmentation of the inflammatory events associated with a specific disease or drug. This Lipid Mediator Signature (LMS) technology has application across all inflammatory diseases, both chronic and acute and will significantly impact patient management and treatment.
Company Details
- Founded
- -
- Address
- London, Gb
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.resolomics.com/
- HQ
- London
Resolomics Questions
Resolomics's website is https://www.resolomics.com/
Resolomics's LinkedIn profile is https://uk.linkedin.com/company/resolomics
Resolomics's industry is
Biotechnology Research
Resolomics's top competitors are
Corp 887,
Core Precision,
Oxford University Innovation,
Companion Diagnostics, Inc.,
In Silico Genesis Ltd,
Unilabs Pharma Solutions,
Atelix Ltd,
Compandx Ltd.
Resolomics's categories are Biotechnology Research
Resolomics's founding year is 2019
